1887

Abstract

SUMMARY

Four neutralizing monoclonal antibodies (MAbs), recognizing three functionally independent, conformational sites on type O foot-and-mouth disease virus (FMDV) failed to react with immobilized structural proteins or synthetic peptides but bound to the isolated capsid protein VP1 and peptides in solution. Inhibition ELISA techniques were, therefore, applied using peptide antigens and anti-peptide sera to block MAb binding to virus particles, permitting the identification of those portions of the VP1 protein contributing to the epitopes. The binding site of one MAb, which neutralized a range of type O FMDV isolates, was shown to have components within regions 146 to 150 and 200 to 213 of VP1 with a critical involvement of the amino acids at positions 146 and 206 or 207. The determinants recognized by two other MAbs which were directed at similar, but not identical, epitopes from a second site included components from the 200 to 213 and 143 to 146 regions with amino acids 143 and 144, respectively, appearing critical for the inhibition of the virus binding of the two antibodies. These results demonstrate that the two previously identified immunogenic tracts of VP1 are brought into proximity in the quaternary structure of the virion to form an antigenic domain containing several conformational epitopes, some of which are functionally independent. A fourth, strain-specific MAb was effectively blocked from reacting with virus by peptides corresponding to residues 161 to 180 and 200 to 213.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/0022-1317-70-6-1493
1989-06-01
2022-08-17
Loading full text...

Full text loading...

/deliver/fulltext/jgv/70/6/JV0700061493.html?itemId=/content/journal/jgv/10.1099/0022-1317-70-6-1493&mimeType=html&fmt=ahah

References

  1. Acharya R., Fry E., Stuart D., Fox G., Rowlands D., Brown F. 1989; The three-dimensional structure of foot-and-mouth disease virus at 2·9 Å resolution. Nature, London 337:709–716
    [Google Scholar]
  2. Al Moudallal Z., Briand J. P., Van Regenmortel M. H. V. 1982; Monoclonal antibodies as probes of the antigenic structure of tobacco mosaic virus. EMBO Journal 1:1005–1010
    [Google Scholar]
  3. Bachrach H. L., Moore D. M., Mckercher P. D., Polatnick J. 1975; Immune and antibody responses to an isolated capsid protein of foot-and-mouth disease virus. Journal of Immunology 115:1636–1641
    [Google Scholar]
  4. Barnett P. V., Ouldridge E. J., Rowlands D. J., Brown F., Parry N. R. 1989; Neutralizing epitopes of type O foot-and-mouth disease virus. I. Identification and characterization of three functionally independent, conformational sites. Journal of General Virology 70:1483–1491
    [Google Scholar]
  5. Bittle J. L., Houghten R. A., Alexander H., Shinnick T. M., Sutcliffe J. G., Lerner R. A., Rowlands D. J., Brown F. 1982; Protection against foot-and-mouth disease by immunisation with a chemically synthesized peptide predicted from the viral nucleotide sequence. Nature, London 298:30–33
    [Google Scholar]
  6. Brown F., Cartwright B. 1963; Purification of radioactive foot-and-mouth disease virus. Nature, London 199:1168–1170
    [Google Scholar]
  7. Diamond D. C., Jameson B. A., Bonin J., Kohara M., Abe S., Itoh H., Komatsu T., Arita M., Kuge S., Osterhaus A. D. M. E., Crainic R., Nomoto A., Wimmer E. 1985; Antigenic variation and resistance to neutralization in poliovirus type 1. Science 229:997–1005
    [Google Scholar]
  8. Di Marchi R., Brooke G., Gale C., Cracknell V., Doel T., Mowat N. 1986; Protection of cattle against foot-and-mouth disease by a synthetic peptide. Science 232:639–641
    [Google Scholar]
  9. Doel T. R., Gale C., Brooke G., Di Marchi R. 1988; Immunization against foot-and-mouth disease with synthetic peptides representing the C-terminal region of VP1. Journal of General Virology 69:2403–2406
    [Google Scholar]
  10. Erickson B. W. A., Merrifield R. B. 1976; In The Proteins. 255 Neurath H., Hill R. L. New York & London: Academic Press;
    [Google Scholar]
  11. Francis M. J., Fry C. M., Rowlands D. J., Bittle J. L., Houghten R. A., Lerner R. A., Brown F. 1987; Immune response to uncoupled peptides of foot-and-mouth disease virus. Immunology 61:1–6
    [Google Scholar]
  12. Fox G., Stuart D., Acharya K. R., Fry E., Rowlands D. J., Brown F. 1987; Crystallization and preliminary X-ray diffraction analysis of foot-and-mouth disease virus. Journal of Molecular Biology 196:591–597
    [Google Scholar]
  13. Fox G., Parry N. R., Barnett P. V., Mcginn B., Rowlands D. J., Brown F. 1989; The cell attachment site on foot-and-mouth disease virus includes the amino acid sequence RGD (arginine-glycine-aspartic acid). Journal of General Virology 70:625–637
    [Google Scholar]
  14. Geysen A. M., Meloen R. H., Barteling S. I. 1984; Use of peptide synthesis to probe viral antigens for epitopes to a resolution of a single amino acid. Proceedings of the National Academy of Sciences, U.S.A 81:3998–4002
    [Google Scholar]
  15. Geysen A. M., Barteling S. J., Meloen R. H. 1985; Small peptides induce antibodies with a sequence and structural requirement for binding antigen comparable to antibodies raised against the native protein. Proceedings of the National Academy of Sciences, U.S.A 82:178–182
    [Google Scholar]
  16. Hogle J. M., Chow M., Filman D. J. 1985; The three-dimensional structure of poliovirus at 2.9 Å resolution. Science 229:1358–1365
    [Google Scholar]
  17. Houghten R. A. 1985; General method for the rapid solid phase synthesis of large numbers of peptides: specificity of antigen-antibody interactions at the level of individual amino acids. Proceedings of the National Academy of Sciences, U.S.A 82:5131–5135
    [Google Scholar]
  18. Laemmli U. K. 1970; Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature, London 111:680–685
    [Google Scholar]
  19. Laporte J., Grosclaude J., Wantyghem I., Bernard S., Rouze P. 1973; Neutralisation en culture cellulaire du pouvoir infectieux du virus de la fievre aphteuse par des serums provenant de pores immunises a l’aide d’une proteine virale purifee. Comptes rendus hebdomadaires des seances de I’Academie des sciences 276D:3399–3402
    [Google Scholar]
  20. Mccullough K. C., Crowther J. R., Butcher R. N. 1985; Alteration in antibody reactivity with foot-and-mouth disease virus (FMDV) 146S antigen before and after binding to a solid phase or complexing with specific antibody. Journal of Immunological Methods 82:91–100
    [Google Scholar]
  21. Makoff A., Paynter C, Rowlands D. J., Boothroyd J. 1982; Comparison of the amino acid sequence of the major immunogen from three serotypes of foot-and-mouth disease virus. Nucleic Acids Research 10:8285–8295
    [Google Scholar]
  22. Minor P. D., Schild G. C., Bootman J., Evans D. M. A., Ferguson M., Spitz M., Stanway G., Cann A. J., Hauptmann R., Clarke L. D., Mountford R. C., Almond J. W. 1983; Location and primary structure of a major antigenic site for poliovirus neutralization. Nature, London 301:674–679
    [Google Scholar]
  23. Morrell D. J. 1983 Studies on the structure and immunogenicity of foot-and-mouth disease virus. Ph.D. Thesis University of Reading;
    [Google Scholar]
  24. Nicolaisen-Strauss K., Kumar H. P. M., Fitting T., Grant C. K., Elder J. H. 1987; Natural feline leukaemia virus variant escapes neutralization by a monoclonal antibody via an amino acid change outside the antibody-binding epitope. Journal of Virology 61:3410–3415
    [Google Scholar]
  25. Ouldridge E. J., Barnett P. V., Rweyemamu M. M. 1982; The relative efficiency of two ELISA techniques for the titration of FMD antigen. Current Topics in Veterinary Medicine and Animal Science 22:142–151
    [Google Scholar]
  26. Ouldridge E. J., Parry N. R., Barnett P. V., Bolwell C., Rowlands D. J., Brown F., Bittle J. L., Houghten R. A., Lerner R. A. 1986; Comparison of the structures of the major antigenic sites of foot-and-mouth disease viruses of two different serotypes. In Vaccines ’86; New Approaches to Immunization45–50 Brown F., Chanock R. M., Lerner R. A. New York: Cold Spring Harbor Laboratory;
    [Google Scholar]
  27. Page G. S., Mosser A. G., Hogle I. M., Filman D. J., Rueckert R. R., Chow M. 1988; Three-dimensional structure of poliovirus serotype 1 neutralizing determinants. Journal of Virology 62:1781–1794
    [Google Scholar]
  28. Parry N. R., Ouldridge E. J., Barnett P. V., Rowlands D. J., Brown F., Bittle J., Houghten R. A., Lerner R. A. 1985; Identification of neutralizing epitopes of foot-and-mouth disease virus. In Vaccines ’85; Molecular and Chemical Basis of Resistance to Parasitic, Bacterial and Viral Diseases211–216 Lerner R. A., Chanock R. M., Brown F. New York: Cold Spring Harbor Laboratory;
    [Google Scholar]
  29. Parry N. R., Syred A., Rowlands D. J., Brown F. 1988; A high proportion of anti-peptide antibodies recognise foot-and-mouth disease virus particles. Immunology 64:567–572
    [Google Scholar]
  30. Pfaff E., Mussgay M., Bohm H. O., Schulz G. F., Schaller H. 1982; Antibodies against a preselected peptide recognise and neutralise foot-and-mouth disease virus. EMBO Journal 1:869–874
    [Google Scholar]
  31. Robertson B. H., Morgan D. O., Moore D. M. 1984; Location of neutralizing epitopes defined by monoclonal antibodies generated against the outer capsid polypeptide, VP1, of foot-and-mouth disease virus A12. Virus Research 1:489–500
    [Google Scholar]
  32. Sherry B., Mosser A. G., Colonno R. J., Rueckert R. R. 1986; Use of monoclonal antibodies to identify four neutralisation immunogens on a common cold picornavirus, human rhinovirus 14. Journal of Virology 57:246–257
    [Google Scholar]
  33. Strohmaier K., Franze R., Adam K.-H. 1982; Location and characterization of the antigenic portion of the FMDV immunizing protein. Journal of General Virology 59:295–306
    [Google Scholar]
  34. Xie Q.-C., Mccahon D., Crowther J. R., Belsham G. J., Mccullough K. C. 1987; Neutralization of foot-and-mouth disease virus can be mediated through any of at least three separate antigenic sites. Journal of General Virology 68:1637–1647
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/0022-1317-70-6-1493
Loading
/content/journal/jgv/10.1099/0022-1317-70-6-1493
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error